Changing paradigm of prophylaxis with longer acting factor concentrates-Reference-Cited by-同舟云学术

Changing paradigm of prophylaxis with longer acting factor concentrates

Published:2014-04-25 Issue: Volume:20 Page:99-105
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Carcao M.¹

Affiliation:

1. Division of Haematology/Oncology; Department of Pediatrics; Child Health Evaluative Sciences; Research Institute; The Hospital for Sick Children; Toronto ON Canada

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12405/fullpdf

Reference49 articles.

1. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate;Pool;Nature,1964

2. Recombinant clotting factors;Pipe;Thromb Haemost,2008

3. The hope and reality of long-acting hemophilia products;Pipe;Am J Hematol,2012

4. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study;Poon;Thromb Haemost,2002

5. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B;Nilsson;J Intern Med,1992

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis;Human Gene Therapy;2024-02-01

2. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults;Research and Practice in Thrombosis and Haemostasis;2023-08

3. Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients;Research and Practice in Thrombosis and Haemostasis;2023-05

4. A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A;The Journal of Clinical Pharmacology;2021-11-08

5. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients;European Journal of Clinical Pharmacology;2021-10-15